维多珠单抗治疗肛周克罗恩病:151例多中心队列研究
这项全国性多中心队列研究纳入151例接受维多珠单抗的肛周克罗恩病患者,其中102例为活动性病变。6个月时活动性肛周病变的临床成功率为22.5%,49例非活动性患者中30.6%出现复发。既往生物制剂数量≥3和起始时未用抗生素与治疗成功相关。
要点
- 活动性肛周克罗恩病患者中,维多珠单抗6个月临床成功率仅22.5%。
- 非活动性肛周病变患者中,30.6%出现复发,中位复发时间22周。
- 既往生物制剂≥3种降低成功概率,起始未用抗生素与成功相关。
核心结论
- 维多珠单抗在活动性肛周克罗恩病患者中成功率低,非活动性患者中近三分之一出现复发。
研究设计与样本
- 全国性多中心队列研究,纳入151例接受维多珠单抗的肛周克罗恩病患者。
- 活动性肛周病变102例,其中男性33例(32.4%),平均年龄39.8岁,平均病程14.6年。
- 101例(99%)既往至少使用过一种抗TNF制剂,中位随访52周。
主要发现
- 活动性肛周病变患者中,维多珠单抗成功(6个月时临床检查无引流瘘管且原发灶无肛周溃疡,未接受药物或手术治疗)为23/102(22.5%)。
- 起始时留置挂线的患者中,9/61(15%)成功拔除挂线。
- 非活动性肛周病变患者49例中,15/49(30.6%)出现肛周病变复发,11/49(22.4%)需要针对性治疗,中位复发时间22周。
关键数值与推荐
- 多因素分析中,既往生物制剂数量≥3与成功相关(OR 0.20,95%CI 0.04-0.98)。
- 起始时未使用抗生素与成功相关(OR 4.76,95%CI 1.25-18.19)。
临床怎么用
- 对于活动性肛周克罗恩病且既往多种生物制剂失败的患者,维多珠单抗成功率较低,需谨慎评估预期。
- 起始时未用抗生素与更高成功概率相关,但需结合临床情况判断。
- 非活动性肛周病变患者接受维多珠单抗期间仍需监测复发,中位复发时间约22周。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of Crohn's disease patients with perianal lesions and anti-TNF failure is challenging. AIMS: To assess the effectiveness of vedolizumab in perianal Crohn's disease and the predictors of success in a real-life cohort. METHODS: We conducted a nationwide multicentre cohort study in patients with perianal Crohn's disease who received vedolizumab. In patients with active perianal Crohn's disease, the success of vedolizumab was defined by clinical success (no draining fistula at clinical examination and no anal ulcers for primary lesions) at 6 months without medical or surgical treatment for perianal Crohn's disease. Logistic regression analyses were performed to identify predictors of success. In patients with inactive perianal Crohn's disease, recurrence was defined by the occurrence of lesions and/or the need for medical or surgical treatments. RESULTS: One hundred and fifty-one patients were included. Among them 102 patients had active perianal disease, 33 (32.4%) males, mean age 39.8 years, mean Crohn's disease duration 14.6 years; 101 (99%) had received at least one anti-TNF. The median follow-up time was 52 weeks. Sixty-eight per cent of patients discontinued therapy after a median time of 33 weeks. Vedolizumab success was reached in 23/102 (22.5%). Among patients with setons at initiation, 9/61(15%) had a successful removal. In multivariable analysis, factors associated with success were the number of prior biologic agents (≥3, odds ratio, OR: 0.20, 95% CI 0.04-0.98) and no antibiotics at initiation (OR: 4.76, 95% CI 1.25-18.19). In 49 patients with inactive perianal Crohn's disease, perianal disease recurred in 15/49 (30.6%), 11/49 (22.4%) needed dedicated treatments. Median time to recurrence was 22 weeks. CONCLUSIONS: We identified a low rate of success of vedolizumab in patients with active perianal Crohn's disease, and nearly one third of patients with inactive perianal Crohn's disease had perianal recurrence. Further evaluation is warranted in prospective studies.
引用
- Chapuis-Biron C, Bourrier A, Nachury M, et al. Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. Aliment Pharmacol Ther. 2020. PMID: 32080886. doi:10.1111/apt.15665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。